First Time Loading...

Amicus Therapeutics Inc
NASDAQ:FOLD

Watchlist Manager
Amicus Therapeutics Inc Logo
Amicus Therapeutics Inc
NASDAQ:FOLD
Watchlist
Price: 10.085 USD 0.95% Market Closed
Updated: May 1, 2024

Amicus Therapeutics Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Amicus Therapeutics Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Amicus Therapeutics Inc
NASDAQ:FOLD
Revenue
$399.4m
CAGR 3-Years
15%
CAGR 5-Years
34%
CAGR 10-Years
105%
Abbvie Inc
NYSE:ABBV
Revenue
$54.3B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.1B
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
9%
Amgen Inc
NASDAQ:AMGN
Revenue
$28.2B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$9.9B
CAGR 3-Years
17%
CAGR 5-Years
26%
CAGR 10-Years
23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.1B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
20%

Amicus Therapeutics Inc
Revenue Breakdown

Breakdown by Geography
Amicus Therapeutics Inc

Total Revenue: 399.4m USD
100%
Ex-United States: 252.4m USD
63.2%
United States: 146.9m USD
36.8%

Breakdown by Segments
Amicus Therapeutics Inc

Not Available

See Also

What is Amicus Therapeutics Inc's Revenue?
Revenue
399.4m USD

Based on the financial report for Dec 31, 2023, Amicus Therapeutics Inc's Revenue amounts to 399.4m USD.

What is Amicus Therapeutics Inc's Revenue growth rate?
Revenue CAGR 10Y
105%

Over the last year, the Revenue growth was 21%. The average annual Revenue growth rates for Amicus Therapeutics Inc have been 15% over the past three years , 34% over the past five years , and 105% over the past ten years .